NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

Gergely Varga, G. Mikala, H. Andrikovics, Magdalena Koszarska, Katalin Balassa, Emma Ádám, András Kozma, A. Tordai, T. Masszi

Research output: Article

8 Citations (Scopus)

Abstract

Summary: Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression-free survival (PFS) was 790 (659-921) d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 (515-733) d in deletion-carriers (I/D&D/D, n = 196, P = 0·013). In multivariate analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard ratio of 0·622 (0·457-0·847), P = 0·003, in addition to international staging system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age and bortezomib treatment. I/I patients benefited more from bortezomib treatment [PFS 902 (703-1101) and 580 (343-817), P = 0·008] than I/D&D/D patients [PFS 659 (487-831) and 488 (323-653), P = 0·531]; in addition the beneficial effect of low ISS score was not observed in the I/D&D/D group [PFS 639 (454-824) and 650 (458-842), P = 0·226], while it was clear in I/I patients [PFS 1140 (803-1477) and 580 (408-752), P <0·001]. We conclude that homozygous carriers of the insertion allele of the NFKB1 -94ins/delATTG polymorphism have a better prognosis and probably benefit more from bortezomib treatment than MM patients carrying the deletion allele.

Original languageEnglish
Pages (from-to)679-688
Number of pages10
JournalBritish Journal of Haematology
Volume168
Issue number5
DOIs
Publication statusPublished - márc. 1 2015

Fingerprint

Multiple Myeloma
Disease-Free Survival
Alleles
NF-kappa B
Fluorescence In Situ Hybridization
Therapeutics
Multivariate Analysis
Genotype
Survival
Bortezomib

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. / Varga, Gergely; Mikala, G.; Andrikovics, H.; Koszarska, Magdalena; Balassa, Katalin; Ádám, Emma; Kozma, András; Tordai, A.; Masszi, T.

In: British Journal of Haematology, Vol. 168, No. 5, 01.03.2015, p. 679-688.

Research output: Article

Varga, Gergely ; Mikala, G. ; Andrikovics, H. ; Koszarska, Magdalena ; Balassa, Katalin ; Ádám, Emma ; Kozma, András ; Tordai, A. ; Masszi, T. / NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. In: British Journal of Haematology. 2015 ; Vol. 168, No. 5. pp. 679-688.
@article{ea93a9687757414fa4d4b4a17975610a,
title = "NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma",
abstract = "Summary: Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression-free survival (PFS) was 790 (659-921) d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 (515-733) d in deletion-carriers (I/D&D/D, n = 196, P = 0·013). In multivariate analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard ratio of 0·622 (0·457-0·847), P = 0·003, in addition to international staging system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age and bortezomib treatment. I/I patients benefited more from bortezomib treatment [PFS 902 (703-1101) and 580 (343-817), P = 0·008] than I/D&D/D patients [PFS 659 (487-831) and 488 (323-653), P = 0·531]; in addition the beneficial effect of low ISS score was not observed in the I/D&D/D group [PFS 639 (454-824) and 650 (458-842), P = 0·226], while it was clear in I/I patients [PFS 1140 (803-1477) and 580 (408-752), P <0·001]. We conclude that homozygous carriers of the insertion allele of the NFKB1 -94ins/delATTG polymorphism have a better prognosis and probably benefit more from bortezomib treatment than MM patients carrying the deletion allele.",
keywords = "NFKB1, Bortezomib, Multiple myeloma, Nuclear factor kappa B, Polymorphism",
author = "Gergely Varga and G. Mikala and H. Andrikovics and Magdalena Koszarska and Katalin Balassa and Emma {\'A}d{\'a}m and Andr{\'a}s Kozma and A. Tordai and T. Masszi",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/bjh.13197",
language = "English",
volume = "168",
pages = "679--688",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

AU - Varga, Gergely

AU - Mikala, G.

AU - Andrikovics, H.

AU - Koszarska, Magdalena

AU - Balassa, Katalin

AU - Ádám, Emma

AU - Kozma, András

AU - Tordai, A.

AU - Masszi, T.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Summary: Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression-free survival (PFS) was 790 (659-921) d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 (515-733) d in deletion-carriers (I/D&D/D, n = 196, P = 0·013). In multivariate analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard ratio of 0·622 (0·457-0·847), P = 0·003, in addition to international staging system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age and bortezomib treatment. I/I patients benefited more from bortezomib treatment [PFS 902 (703-1101) and 580 (343-817), P = 0·008] than I/D&D/D patients [PFS 659 (487-831) and 488 (323-653), P = 0·531]; in addition the beneficial effect of low ISS score was not observed in the I/D&D/D group [PFS 639 (454-824) and 650 (458-842), P = 0·226], while it was clear in I/I patients [PFS 1140 (803-1477) and 580 (408-752), P <0·001]. We conclude that homozygous carriers of the insertion allele of the NFKB1 -94ins/delATTG polymorphism have a better prognosis and probably benefit more from bortezomib treatment than MM patients carrying the deletion allele.

AB - Summary: Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression-free survival (PFS) was 790 (659-921) d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 (515-733) d in deletion-carriers (I/D&D/D, n = 196, P = 0·013). In multivariate analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard ratio of 0·622 (0·457-0·847), P = 0·003, in addition to international staging system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age and bortezomib treatment. I/I patients benefited more from bortezomib treatment [PFS 902 (703-1101) and 580 (343-817), P = 0·008] than I/D&D/D patients [PFS 659 (487-831) and 488 (323-653), P = 0·531]; in addition the beneficial effect of low ISS score was not observed in the I/D&D/D group [PFS 639 (454-824) and 650 (458-842), P = 0·226], while it was clear in I/I patients [PFS 1140 (803-1477) and 580 (408-752), P <0·001]. We conclude that homozygous carriers of the insertion allele of the NFKB1 -94ins/delATTG polymorphism have a better prognosis and probably benefit more from bortezomib treatment than MM patients carrying the deletion allele.

KW - NFKB1

KW - Bortezomib

KW - Multiple myeloma

KW - Nuclear factor kappa B

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84922767744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922767744&partnerID=8YFLogxK

U2 - 10.1111/bjh.13197

DO - 10.1111/bjh.13197

M3 - Article

C2 - 25363231

AN - SCOPUS:84922767744

VL - 168

SP - 679

EP - 688

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -